Medicines Patent Pool, known for its work in the generic licensing of drugs for infectious diseases such as HIV and tuberculosis, has big ambitions for the next three years.
It aims to have 10 new licenses, support 10 technology transfers, and develop five new products that will reach 30 million people by 2025. The goal is to deliver medicines to low- and middle-income countries at the same time as high-income countries.
“I want to get generic versions into low- and middle-income countries within a year of their launch in the developed world. That's really the aim,” Charles Gore, the executive director of MPP, told Devex ahead of the launch of the organization’s new strategy on Monday.